Ohio State hematologist Dr. Kerry Rogers says chemotherapy and newer targeted drugs both work well, and the right choice depends on the patient.
|Articles|December 8, 2011
Video blog: BOLERO-2 and Afinitor in breast cancer
Author(s)Debu Tripathy
Advertisement
Dr. Debu Tripathy explains the updated results of the BOLERO-2 study, which looked at Afinitor (everolimus) and an aromatase inhibitor in metastatic breast cancer. How useful will this new drug be in metastatic breast cancer?
Advertisement
Related to this article
Given an 18-month prognosis for peritoneal mesothelioma in 2007, a mother shares the joy of tapping her son out at his Air Force basic training graduation.
A once-daily oral pill gives patients with symptomatic TGCT another option when surgery could cause more harm than good.
For World NET Cancer Day, CURE answers seven common questions about neuroendocrine tumors, from carcinoid syndrome and Ki-67 to dotatate PET scans and treatment options.
Up to 40% of patients with classic hairy cell leukemia relapse within 10 to 15 years. An NIH researcher explains how adding Rituxan up front may help.
Gita Kwatra, PharmD, MBA, co-founder and CEO of the Glioblastoma Foundation, explains what happens to tumor tissue after brain surgery and how patients can ask their care team for genomic testing.
Most people with pancreatic cancer lose weight they didn't mean to. Here is how weight loss from poor digestion differs from cachexia, and what enzymes, eating strategies and appetite medicines can do.
Dr. Rebecca Dent explains how Datroway kept brain metastases in check longer than chemotherapy in triple-negative breast cancer, and what patients should know.
Advertisement
Advertisement
Trending on CURE
1
FDA Approves Pimicotinib for Tenosynovial Giant Cell Tumor
2
Neuroendocrine Tumors: 7 Questions Patients Ask, Answered
3
Why Rituxan Plus Cladribine May Delay Hairy Cell Leukemia Relapse
4
Datroway Slows Brain Metastases in Triple-Negative Breast Cancer
5